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Abstract
Background: Pancreatic cancer is still associated with devastating prognosis. Real progress in treatment options has 
still not been achieved. Therefore new models are urgently needed to investigate this deadly disease. As a part of this 
process we have established and characterized a new human pancreatic cancer cell line.
Methods: The newly established pancreatic cancer cell line PaCa 5061 was characterized for its morphology, growth 
rate, chromosomal analysis and mutational analysis of the K-ras, EGFR and p53 genes. Gene-amplification and RNA 
expression profiles were obtained using an Affymetrix microarray, and overexpression was validated by IHC analysis. 
Tumorigenicity and spontaneous metastasis formation of PaCa 5061 cells were analyzed in pfp-/-/rag2-/- mice. 
Sensitivity towards chemotherapy was analysed by MTT assay.
Results: PaCa 5061 cells grew as an adhering monolayer with a doubling time ranging from 30 to 48 hours. M-FISH 
analyses showed a hypertriploid complex karyotype with multiple numerical and unbalanced structural aberrations. 
Numerous genes were overexpressed, some of which have previously been implicated in pancreatic adenocarcinoma 
(GATA6, IGFBP3, IGFBP6), while others were detected for the first time (MEMO1, RIOK3). Specifically highly 
overexpressed genes (fold change > 10) were identified as EGFR, MUC4, CEACAM1, CEACAM5 and CEACAM6. 
Subcutaneous transplantation of PaCa 5061 into pfp-/-/rag2-/- mice resulted in formation of primary tumors and 
spontaneous lung metastasis.
Conclusion: The established PaCa 5061 cell line and its injection into pfp-/-/rag2-/- mice can be used as a new model for 
studying various aspects of the biology of human pancreatic cancer and potential treatment approaches for the 
disease.
Background
Pancreatic carcinoma is one of the most lethal neo-
plasms, with an overall 5-year survival rate < 5% [1,2]. Its
incidence nearly equals mortality. This high mortality
rate is due to an unusual aggressiveness, chemoresistance
and early occurrence of metastatic disease. At the time of
diagnosis, only a minority of about 20% of patients are in
a non-metastatic stage of disease, which is the mandatory
prerequisite for potentially curative surgery. To date, the
molecular basis of this aggressive behaviour remains
enigmatic [3,4], and further investigation of pancreatic
cancer biology is of pivotal importance to provide new
insights aiming at developing strategies for its prevention
and treatment.
A major difficulty in studying pancreatic ductal adeno-
carcinoma (PDAC) biology is represented by the peculiar
morphologic traits of the tumor. In fact, PDAC is charac-
terized by a rich desmoplastic reaction. Tumor cells are
often embedded into peritumoral, inflammatory altera-
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tions caused by tumor-associated, ductal obstruction
[5,6]. For this reason, tumor cell lines solely represent a
pragmatic tool consisting of clonal population of tumor
cells with self-renewable features providing a basis for a
variety of biologic and molecular experiments. Neverthe-
less, in vitro studies performed so far have distinct limita-
tions. First, they are accomplished using a limited
number of cancer cell lines, which have been cultured in
vitro for a long time and may have altered their pheno-
and genotypes. Second, many of the cancer cell lines used
in these studies are derived from pancreatic cancer
metastases and not from the original tumor. Third, sev-
eral cell lines differ substantially from the clinical situa-
tion; they are often non-metastatic in conventional
xenograft models. Although pancreatic cancer frequently
metastasizes to regional lymph nodes and the liver in
early tumor stages, only a few cell lines have been
reported to spontaneously metastasize in vivo [7].
In the present study, we report biomolecular character-
istics of a new human pancreatic adenocarcinoma cell
line named PaCa 5061, which spontaneously metasta-
sized into the lungs in a mouse xenograft model. We
describe the cell line in terms of growth characteristics,
phenotype, and genotype for their unique DNA and RNA
profile using Affymetrix microarray technology as well as
for specific alterations of relevant tumor-associated
genes. Additionally, cytogenetic characteristics were
accomplished by karyotype analysis.
Methods
Establishment of cell lines and culture conditions
Primary tumor tissues were taken from a 63-year-old
male patient who underwent total pancreaticoduodenec-
tomy for advanced pancreatic adenocarcinoma. Histo-
pathological examination of the surgical specimen
confirmed a low-differentiated adenocarcinoma of the
pancreas, which was staged pT3, pN1 (7/43), G3, M0, R1.
The patient died 6 weeks after surgery without having
received any chemotherapy. Written informed consent of
the patient for the removal of tissue samples for investiga-
tional purposes was obtained prior to surgery. The study
was approved by the ethical committee of the Medical
Council of Hamburg (Ärztekammer), Germany. Small
fragments of tumor tissue with a diameter of 1 mm were
obtained by mincing the tumor specimen with a scalpel.
The fragments were enzymatically disaggregated after
incubation with 0.5% collagenase type IV (Sigma-Aldrich,
Steinheim, Germany) solution at 37°C on a rotary shaker.
After 45 minutes, the solution was centrifuged at 700 g
for 5 minutes, the pellet was collected, washed twice in
cell culture medium (RPMI, Invitrogen, NY, USA) resus-
p e n d e d  i n  c o m p l e t e  m e d i u m  ( T U M ) ,  t h e n  p l a t e d  i n t o
collagen-coated culture flasks (Becton Dickinson Lab-
ware, Bedford, MA, USA), and cultivated at 37°C in a
humidified atmosphere with 5% CO2. The TUM medium
was comprised of RPMI 1640 with Glutamax (Invitrogen,
NY, USA) supplemented with 10% of fetal calf serum
(FCS), 200 IU/ml of penicillin-streptomycin, 0.1 mg/ml
gentamycin (Biochrom AG, Berlin, Germany), 50 nmol/
ml of human transferrin (Sigma-Aldrich, Steinheim, Ger-
many), 0.01 μg/ml of bovine insulin (Sigma-Aldrich,
Steincheim, Germany), 0.01 μg/ml of recombinant
human epidermal growth factor (Pepro Tech, London,
UK), and 0.01 μg/ml of human basic fibroblast growth
factor (Pepro Tech, London, UK). The growth medium
was replaced every 4 to 7 days, and culture flasks were
regularly checked for epithelial cells and fibroblast out-
growth. The cell line was cultured as monolayers in 25- or
75-cm2  flasks, routinely passed by trypsinization, and
maintained in complete culture medium. Cells at differ-
ent culturing passages were stored in liquid nitrogen in
culture medium containing 10% dimethyl sulfoxide. At
this time the cells underwent 100 passages.
Animals
The methods for carrying out the animal experiments
were performed according to the UKCCR guidelines for
the welfare of animals in experimental neoplasia [8].
Pathogen-free C57BL/6 pfp-/-/rag2-/- mice (4 males and 4
females) aged 14-16 weeks were housed in filter-top
cages: sterile water and food were given ad libitum. Mice
weighed 25-30 g at the beginning of the experiment. All
manipulations were conducted aseptically inside a lami-
nar flow hood. One million PaCa 5061 cells (in 200 μl
RPMI1640 medium without serum and antibiotics) were
injected subcutaneously between the scapulae of each
animal. The mice were killed when the tumor had
reached approximately 10% of their total weight.
Histology
After animals were sacrificed, primary tumors were
excised and fixed in 4% buffered formaldehyde for 24 h,
rinsed with phosphate buffer, dehydrated in a series of
graded ethanol and embedded in paraffin. Sections of 5
μm thickness were cut and stained with haematoxylin
and eosin (H.E.). To achieve a random distribution of
each animal lung, the lungs were excised and fixed en
block and cut into 1 mm thick lung slices. The slices were
placed in warm agar and pressed down with a glass pis-
ton. After hardening of the agar these lung slices were
processed paraffin-embedded as above. The agar blocks
containing the lung slices were cut into 5 μm thick sec-
tions and the total number of sections of each lung was
noted. In addition to every 10th section, two series of
serial sections (n = 30) out of the middle of the paraffin
wax block were preserved for further immunohistological
evaluation. Ten of the 10th sections out of the middle of
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were counted in each of the ten stained sections under a
microscope (Zeiss, Axioplan 2, 200×). The number of
metastases for each mouse was calculated (mean number
of metastasis × total number of sections - 20%), according
to a formula established earlier [9]. To compare the in
vitro grown cells with the in vivo grown tumors, cultured
cells were pelleted and fixed with 4% formaldehyde and
than embedded in agar (Agar Noble, Difco Laboratories,
Detroit, MI, USA). Five μM sections were cut and
mounted onto glass slides for IHC analysis.
Immunostaining
Standard indirect immunoperoxidase procedures were
performed with the peroxidase method according to
manufacturer's protocol (HRP-AEC System, Cell and Tis-
sue Staining Kit; R&D Systems, Minneapolis, MN, USA).
In order to confirm the human origin of even the small-
est metastatic deposits, parallel sections to H.E. stained
sections in which at least one metastasis was observed,
were stained with a monoclonal pan-cytokeratin anti-
body, clone AE1/AE3 (Dako, Carpenteria, CA, USA). For
IHC analysis the following antibodies were used: mono-
clonal CA 19-9, clone 116-NS-19-9, polyclonal rabbit
CEA, and monoclonal EGFR, clone E30 (Dako, Carpente-
ria, CA, USA), monoclonal Mucin 4, clone 5B12 (Abnova,
Taipei, Taiwan), monoclonal CEACAM-5, clone 487609
(R&D, Minneapolis, MN, USA) and monoclonal
CEACAM6, clone 9A6 (Covance, Princeton, NJ, USA).
Flow Cytometry
Cultured PaCa 5061 cells were trypsinized, washed and
stained on ice with phycoerythrin (PE)- conjugated or
fluoresceinisothiocyanate (FITC)-conjugated primary
antibody without fixation. The following antibodies were
used at the concentrations recommended by the manu-
facturer: CD44-FITC, clone B-F24 (Dianova, Hamburg,
Germany); CEACAM1-PE, clone 283340 (R&D, Minne-
apolis, MN, USA); CEACAM5-FITC, clone C365D
3(NCRC23) (AbD Serotec, Düsseldorf, Germany);
CEACAM6-APC, clone 439424 (R&D, Minneapolis, MN,
USA); EGFR-PE, clone EGFR.1 (BD, Heidelberg, Ger-
many); EpCAM-PE, clone 1B7 (eBioscience, Frankfurt,
Germany). The corresponding murine isotype controls
were: IgG1-FITC (Miltenyi, Bergisch-Gladbach, Ger-
many); IgG1-PE (eBioscience, Frankfurt, Germany);
IgG2a-APC (R&D, Minneapolis, MN, USA); IgG2b-PE
(Miltenyi, Bergisch-Gladbach). Flow cytometry was per-
formed using a FACS CALIBUR flow cytometer (Becton
Dickinson, Heidelberg, Germany). Expression profiles
were analyzed using Win MDI 2.9 software.
DNA fingerprinting analyses
The "Gene Print Fluorescent STR Multiplex Kit CSF1PO,
TPOX, THO1 and vWA" (Promega, Madison, WI, USA)
was used to compare patient's DNA to that of the cell line
for excluding possible cross-contaminations with other
cell lines. The PCR was carried out as recommended by
the manufacturer and the PCR products were analyzed
on an automatic sequencer (ABI PRISM 310 Genetic
Analyzer) using the GenScan Analysis Software. The
DNA fingerprinting profile of patient DNA was identical
to this cell line. Comparative analyses of the fingerprint-
ing profile of another cell line showed that this cell line
was unique.
Multicolor Fluorescence In Situ Hybridization (mFISH)
After 15 to 18 passages, the cultured primary cells were
exposed to Colcemid (0,02 μg/ml) (Gibco-Invitrogen,
Karlsruhe, Germany) overnight and subsequently har-
vested. Multicolor fluorescence in situ hybridization
(mFISH) was performed using the 24XCyte color kit for
human chromosomes (MetaSystems, Altlussheim, Ger-
many) following the supplier's recommendations.
Twenty-five well-conserved and complete metaphases
were evaluated and karyotypes were described according
to the International System for Human Cytogenetic
Nomenclature (ISCN 2005).
Affymetrix DNA SNP array analysis and data acquisition
DNA was extracted from punched tissue cylinders from
frozen tumor samples or from pelleted culture cells
according to the manufacturer's instructions of the
QIAmp DNA Mini Kit (Qiagen, Hilden, Germany). DNA
was further processed as described in the Affymetrix
GeneChip Assay manual 6.0 (Affymetrix, Santa Clara,
CA, USA). After hybridization to the GeneChip Genome-
Wide Human single nucleotide polymorphism (SNP)
Array 6.0, the microarray chips were washed and stained
on an Affymetrix fluidics station. The chips were scanned
using Affymetrix GeneChip scanner 3000 7G.
Raw data from scanned SNP arrays were acquired using
the GeneChip Operating Software (Affymetrix). Quality
of the data was checked as described in the GeneChip
Mapping 6.0 Assay manual (Affymetrix). The data files
were imported into the Chip software, and pre-process-
ing and normalization were performed as described in
the user manual. The resulting signal intensities were
imported into R suite (R Development Core Team). Data
were further processed with an especially created analysis
tool using all measurements between 25th and 75th per-
centile as a reference for each DNA spot. Data were then
modified to fit the input requirements of the DNAcopy
package [10] of the Bioconductor suite [11]. The DNA-
copy package was used to calculate and visualize seg-
ments with similar DNA content. Segments with higher
DNA content than above calculated reference were classi-
fied as candidate regions for gene amplification.Kalinina et al. BMC Cancer 2010, 10:295
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RNA isolation and GeneChip® expression analysis
Total RNA from passage 27 of PaCa 5061 cells was iso-
lated using the TRIzol® reagent (Invitrogen, Groningen,
The Netherlands) according to the manufacturer's proto-
col. The dried pellet was resuspended in 100 μl DEPC-
water and used in the cleanup procedure with the RNeasy
MinElute Cleanup Kit (Qiagen, Hilden, Germany). The
cleanup process was followed by an overnight ethanol-
precipitation, including 7.5 M NH4OAc and 2.5 volumes
of absolute ethanol at -20°C. The RNA-pellet was dis-
solved in 10 μl RNase-free water. The RNA-concentration
was measured on a NanoDrop® ND-1000 Spectrophotom-
eter (Peqlab, Erlangen, Germany) and the quality was
checked with the Agilent 2100 Bioanalyzer (Agilent Tech-
nologies, Santa Clara, CA, USA).
Gene expression profiles of the whole human genome
were generated by hybridizing either 5 μg of the isolated
total RNA from the PaCa 5061 or 5 μg of human total
pancreas RNA (Stratagene, La Jolla, CA, USA) serving as
healthy control RNA on GeneChip®  Human Genome
U133 Plus 2.0 Arrays (Affymetrix, Santa Clara, CA). The
analysis was performed according to the One-cycle
cDNA synthesis protocol for GeneChip® Expression Anal-
ysis Manual (Affymetrix), and the achieved data were
analyzed using an Affymetrix GeneChipOperatingSoft-
ware (GCOS) 1.4 and scaled to a default target signal
value of 150. Absolute and comparative analysis was per-
formed using the Affymetrix MAS 5.0 algorithm. Anno-
tations were further analyzed with interactive query
analysis at http://www.affymetrix.com.
Cell viability analysis
To determine the drug sensitivity of the PaCa 5061 cells,
they were incubated with different concentrations (1-10
μmol) of Gemcitabine (Lilly Deutschland GmbH, Gies-
sen, Germany), Cetuximab (Merck, Darmstadt, Ger-
many), Fluorouracil (5-FU) (Sigma-Aldrich, Steinheim,
Germany), or Gefitinib (Astra Zeneca, Macclesfield,
Cheshire, UK), respectively. Cell proliferation was deter-
mined by the CellTiter 96® AQueous One Solution Cell Pro-
liferation Assay (Promega, Madison, WI, USA). Briefly,
the cells were seeded into 96-well culture plates (5000
cells/well) in TUM medium and allowed to attach at 37°C
and 5% CO2 in humidified air for 24 h. The medium was
replaced by the drug containing medium for a subsequent
72 hrs. Each experiment was performed in quadruplicate.
At the end of the incubation time, 20 μl of substrate was
added to every well. The reaction mixture was incubated
at 37°C for 2 h, and the absorbance was measured at 490
nm. Values for control cells were considered as 100% via-
bility. Every measurement was performed at least in three
independent experiments.
Data analysis
Experiments presented in the figures are representative
of three or more different repetitions. The data are pre-
sented as the mean values ± SE.
Results
Establishment of cell lines
A new pancreatic carcinoma cell line designated PaCa
5061 was generated from a resected PDAC. Within the
first 2 weeks, the tumor cell clusters adhered to the sur-
face of the cell culture flasks and gradually formed cell
colonies. Initially, contaminating fibroblastic cells prolif-
erated and surrounded the tumor cell colonies. During
serial passages, the number of fibroblastic cells gradually
decreased and was replaced entirely by tumor cells (Fig-
ure 1A). All cells adhered tightly to the bottom of the cell
culture flasks in a monolayer, and were characterized as
polygonal epithelial-like cells with large nuclei containing
several nucleoli. The appearance of PaCa 5061 cells was
polygonal. The population doubling time ranged from 30
Figure 1 Cell morphology and growth characteristics of PaCa 
5061 cells. 1A. Morphological examination of non-confluent and con-
fluent PaCa 5061 cells by phase contrast microscopy. The cells grew in 
a monolayer with polygonal shape, epithelial morphology and large 
nuclei. 1B. Growth curve of PaCa 5061 in culture. Proliferation of cells 
(1000/well) was determined every 24 hours and relative growth rates 
were analyzed over time (0-144 h) by MTT assay. The results shown are 
for an experiment representative of three independent assays.
B
A
M
T
T
 
a
s
s
a
y
(
a
b
s
o
r
b
a
n
c
e
 
a
t
 
 
4
9
0
 
n
m
)
0.00
0.20
0.40
0.60
0.80
1.00
1.20
0h 24h 48h 72h 96h 120h 144hKalinina et al. BMC Cancer 2010, 10:295
http://www.biomedcentral.com/1471-2407/10/295
Page 5 of 13
Figure 2 Immunostaining and cell surface expression of epithelial/pancreatic markers and overexpressed proteins in PaCa 5061 cells. 2A. 
The formaldehyde fixed and agar embedded cells were immunostained for the presence of pancreatic cancer markers CA 19-9 and CEA respectively, 
as well as for cytokeratin as epithelial cell marker proteins (upper panel). Several on RNA-level overexpressed genes (Microarray) were chosen. To con-
firm protein overexpression of selected amplified genes in PaCa 5061 cells immunostaining was performed for Mucin4, EGFR and CEACAM 6 (lower 
panel). 2B. FACS profiles of PaCa 5061 cells. Cell surface expression of CD44, EpCAM, EGFR, CEACAM1, CEACAM5 and CEACAM6 were obtained with 
specific antibodies as in materials and methods. Each histogram shows cell surface expression of the corresponding marker (filled curves) and the 
irrelevant, isotype-matched antibody (open curves).Kalinina et al. BMC Cancer 2010, 10:295
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to 48 hours (Figure 1B). The epithelial phenotype was
confirmed by the positive immunoreactivity for cytokera-
tin and the expression of the pancreatic tumor markers
CEA and CA 19-9 (Figure 2A). The same pattern of
immunoreactivity was observed in the primary tumor of
patient. FACS analysis of PaCa 5061 cell population
revealed homogeneous expression levels for EpCAM
(98.7%), CD44 (100%), EGFR (83.5%) as well as CEACAM
1 (93.3%) whereas heterogeneous expression levels was
observed for CEACAM 5 (24.7%) and CEACAM 6
(69.7%) (Figure 2B).
Multicolor fluorescence in situ hybridization and molecular 
genetic analyses
An abnormal hypertriploid complex karyotype was
detected in all analyzed metaphases of the PaCa 5061 cell
line (Figure 3). The karyotype was as follows: 78 < 3n+ >
,XX,-Y,der(1)t(1;9)(p35;?),+2,del(2)(p21)x2,+3,der(3)t
(3;12)(p11;?)x2,+5,+7,del(7)(q22)x2,der(8)t(8;16)(p11;?),+
del(9)(p13),del(9)(p13),der(9;10)(q10;q10)x2,10,der(10)t(
10;16)(q11;?)x2,+11,+12,del(12)(q15)x2,+14,+15,+17,der(
17)t(8;17)(?;p11)x2,-18,+19,+20,-21,+22[cp25]. Almost all
chromosomes were affected by numerical or structural
changes. Numerical abnormalities were found more fre-
quently than structural rearrangements, and chromo-
somal gains were more frequent than losses. Six
unbalanced translocations involving chromosomes 1, 3,
8, 9, 10, and 17 were seen, however, balanced transloca-
tions were absent. The identifiable breakpoints of the
unbalanced translocations were located in the chromo-
somal regions 1p35, 3p11, 8p11, 9q10, 10q10/q11, and
17p11. Whole chromosome gains of chromosomes 5, 11,
14, 15, 20, and 22 as well as partial chromosome gains of
2, 3, 7, 8, 9, 12, 16, and 17 were observed in this cell line.
Whole chromosome losses affected chromosomes Y, 10,
18, and 21, and partial losses were detected for chromo-
somes 2, 3, 7, 8, 9, 12, and 17.
The cytogenetic findings were correlated and extended
by the DNA-SNP array data. As expected, imbalances tar-
geting small chromosomal regions remained beyond the
limits of detection of mFISH.
An activating mutation was found in codon 12 of the K-
ras gene. The PaCa 5061 had a G to A homozygous tran-
sition (GGT(gly) > GAT(asp)), while no inactivating
mutations were found in TP53, exon 4, 5, 6, 7, 8, 9 and
EGFR exon 18-21. A polymorphism at codon 72 (CGC-
arg) of p53 was also noticed in PaCa 5061 cells.
Copy number variations and differential gene expression
The Affymetrix 6.0 SNP array was used to identify the
genes amplified in PaCa 5061 cells and primary tumor
DNA. The DNA profile of PaCa 5061 cells and the pri-
mary tumor of the same patient are shown in Figure 4.
Although there are much stronger DNA copy number
variations (CNV) in the cell line as compared to the pri-
mary tumor sample, the general patterns of CNV were
Figure 3 mFish analysis of PaCa 5061 cells. mFish analysis of PaCa 5061 cells. Representative karyotype of PaCa 5061 cells. Multiple numerical 
and unbalanced structural aberrations were observed in the majority of cells. Note. Whole-chromosome losses of 18, 21 and Y, as well as, gains of chro-
mosomes 11 and 20 are frequently found in pancreatic cancer.Kalinina et al. BMC Cancer 2010, 10:295
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highly similar. The DNA profile showed a considerable
number of large chromosomal alterations, including dele-
tions involving at least parts of chromosomes 1p, 2p, 3p,
7q, 8p, 9p, 10, 12q, 17p, 18, and 21. In addition, gains were
found at chromosomes 8q, 12p, 14, 16, 17q, 4 and 22.
Chromosomal areas of high level gene amplification were
found at 2p22, cen6, 7q21, 10p12, 10q11, 12q13, 12q14,
and 18q11. The exact amplicon positions and affected
genes are summarized in Table 1.
The gene expression profile of the PaCa 5061 cell line
was compared to the RNA expression pattern obtained
from normal pancreas. In total, 7012 genes were overrep-
Figure 4 Whole-genome DNA profile of PaCa 5061. The DNA profile performed by Affymetrix GeneChip hybridization shows a considerable num-
ber of large chromosomal alterations. Detailed candidate regions of gene amplification and affected genes are listed in Table 1.
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Table 1: Amplicon positions and affected genes
Localization Amplicon position (pb) Copy number variations Putative target gene (s)
2p22 31168964-32709448 11 MEMO1
7q21 88495972-89700934 2 STEAP2
10p12 26552050-30207158 17 RAB18
10q11 41956473-44148144 11 RET
12q13 50980560-56120694 143 ERBB3
IGFBP6
STAT2
STAT6
MMP19
MAP3K12
12q14 62947641-64014306 7 TBK1
18q11 17336609-18060812 6 GATA6
MIB1
RIOK3Kalinina et al. BMC Cancer 2010, 10:295
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resented more than 1.5-fold and 4212 were down-regu-
lated at least 1.5-fold. In general, the down-regulated
genes represent the pancreas-specific genes involved into
metabolic pathways such as glycolysis and gluconeogene-
sis. The suppression of these genes could be associated
with the dedifferentiation of pancreatic cells during
malignant transformation. Most of the upregulated genes
represent different proteins associated with cell prolifera-
tion and resistance to apoptosis, as growth factor recep-
tors (EGFR, IGF-IR), different kinases (AKT, MAPK), and
growth factors (amphiregulin, HBEGF, epiregulin,
VEGF). Some pro-angiogenic factors (IL18, IL15,
MMP10, MMP28) as well as cell adhesion molecules
(CEACAM 1, CEACAM 5, CEACAM 6) were also over-
expressed. The fold changes of some selected genes are
shown in Additional file 1. The highest overexpression
concerned the surface protein Mucin 4 (MUC4), which is
involved in the regulation of cell adhesion. As expected,
some amplified genes (MEMO1, IGFP6, TBK1, MIB1,
RIOK3), determined by the DNA chip array demon-
strated high level of RNA overexpression as well.
Tumorigenicity and metastatic ability of the PaCa 5061 cells
To assess the in vivo tumorigenic potential of PaCa 5061
cells, 1×106  cells were transplanted subcutaneously
between the scapulae of immunodeficient pfp-/-/rag2-/-
mice. After 14-23 weeks, all mice developed local tumors
at the site of injection. No macroscopically detectable
metastases were detected at necropsy, however, histologi-
cal examination of animals´ lungs revealed the presence
of numerous metastases in 6 out of 8 mice (Table 2). The
median number of metastases was 724 with a range from
24 to 1948. The pancreatic carcinoma cell markers
(cytokeratins, CA 19-9) as well as the other overexpressed
proteins identified in PaCa 5061 cell line (MUC 4, EGFR,
CEACAM 1, -5, and -6) were analyzed by IHC in mouse
primary tumor and corresponding metastasis and com-
pared with the expression of this marker in the primary
tumor of the patient. The pattern of the staining intensi-
ties as well as the expression patterns showed a high level
of similarity between human and mouse primary tumor
(Figure 5A and 5B).
Drug sensitivity
We examined the cellular sensitivity of PaCa 5061 cells to
different drugs in vitro using the proliferation assay. PaCa
5061 cells were treated with increasing concentrations of
the chemotherapeutic drugs Gemcitabine (0.1-10 μM)
and 5-FU (0.1-10 μM). PaCA 5061 cells exhibited native
resistance to both drugs and inhibiton of cell proliferation
to 50% (IC50) was achieved with 10 μM for Gemcitabine
and > 10 μM for 5-FU respectively (Figure 6A). As PaCa
5061 cells were characterized by an elevated expression
level of EGFR, we blocked EGFR activation by a tyrosin-
kinase inhibitor (Gefitinib) or EGF binding by a monoclo-
nal EGFR antibody (Cetuximab). PaCa 5061 cells showed
robust resistance to these drugs, and IC50 was achieved
with > 15 μM for Gefitinib and > 10 μg/ml for Cetuximab
(Figure 6B).
Discussion
The biology of PDAC is poorly understood. Primary
tumor cell lines serve as an available preclinical research
tool for a better understanding of several tumor-related
pathological aspects and the evaluation of anticancer
agents [12]. However, the impact of such studies is often
limited because information concerning the original
tumor from which the cell lines were derived is scarce.
Many mammalian cell lines, serving as the basic platform
for investigations in biomedical research, have been cul-
tured for more than 40 years. The proportion of research
papers flawed by the use of misidentified and cross-con-
taminated cell cultures accounts for approximately 15-
25% [13,14]. In this study we complied with the evident
need for new cancer cell lines which reliably reflect the
clinical features of pancreatic cancer such as molecular
biomarkers and metastatic behaviour.
The first report on successful cultivation of a human
pancreatic cancer cell line dates back to 1963 [15]. Since
then, well over 60 human pancreatic cancer cell lines have
been reported [16]. Only a few of these cell lines (Capan-
1, SUIT-2, SUIT-4 and PCT-1) have been described to
metastasize spontaneously in vivo into the regional
lymph nodes or distant organs such as liver, lung or peri-
toneal cavity in nude mouse subcutaneous xenograft
models [17]. In this context Loukopoulos et al. have pre-
viously shown that orthotopic injection of such cell lines
in SCID mice resulted in extensive local tumor growth
and metastatic spread [18].
I t  i s  w i d e l y  a c c e p t e d  t h a t  x e n o g r a f t  m o u s e  m o d e l s
which feature cancer cells growing in their natural loca-
tion resemble the clinical situation closer than subcuta-
neous mouse models including (i) extensive local tumor
growth, (ii) metastases to the liver and regional lymph
nodes, and (iii) distant metastases to the diaphragm and
mediastinal lymph nodes. Although orthotopic implanta-
tion models are preferred over subcutaneous models,
previous studies have shown that orthotopic implanta-
tion has more potential for complications and is often
affiliated with a varying rate of tumorigenicity and metas-
tasis formation in vivo [19]. Nevertheless, subcutaneously
injected cancer cells grow well at heterotopic sites but
they infrequently adopt the real clinical situation as they
are often non-metastatic. Therefore, our newly estab-
lished PaCa 5061 cell line is one of very few cell lines
capable to spontaneously metastasize into the lung of pfp-
/-/rag2-/- m i c e  w i t h  h i g h  e f f i c i e n c y  a f t e r  s u b c u t a n e o u sKalinina et al. BMC Cancer 2010, 10:295
http://www.biomedcentral.com/1471-2407/10/295
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Figure 5 Immunostaining of primary Patient Tumor in comparison to xenografts of PaCa 5061 cells in pfp-/-/rag2-/- mice. Primary patient tu-
mor as wells as primary mouse tumor and corresponding lung metastasis were immunostained. 5A. Human primary tumor, mouse tumor and corre-
sponding lung metastasis are positive for cytokeratin and pancreatic cancer cell markers CEA and CA 19-9 respectively. Positive immunostainings for 
overexpressed Mucin4 are shown, confirming the Microarray data. 5B. Patient primary tumor as well as mouse tumors are highly positive for EGF re-
ceptor as well as for CEACAM 5, and -6 adhesion molecules, confirming the Microarray data. Remarkably, the pattern of the staining intensity as well 
as the expression pattern showed a high level of similarity between human and mouse primary tumor.Kalinina et al. BMC Cancer 2010, 10:295
http://www.biomedcentral.com/1471-2407/10/295
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transplantation. Hence, this cell line reliably reflects the
clinical situation and is therefore capable to investigate
the complex biology of pancreatic cancer progression,
cancer cell dissemination and metastasis formation as
well as chemoresistance of this deadly neoplasia in vivo,
even without application of an orthotopic implantation
model.
The PaCa 5061 cell line, derived from a PDAC, was
immunoreactive for general epithelial cell markers such
as cytokeratins, the epithelial cell adhesion molecule
(EpCAM), MUC4 which is involved in the regulation of
cell adhesion and membrane-bound glycoprotein CD44.
Furthermore, more specific pancreatic tumor markers,
such as CA 19-9 and CEA were displayed by the cells
confirming their organic origin. The ability of these cells
to form tumors in pfp-/-/rag2-/- mice proved their tumori-
genic potential. In addition, the highly invasive and
aggressive behaviour of these cells was demonstrated by
their ability to form metastases in 75% of the test animals.
The histopathological profile of the primary xenograft
tumor obtained after injection of PaCa 5061 cells strongly
resembles that of the original tumor. This finding was in
line with previous results reported from ovarian carci-
noma, where patient samples and mouse xenotransplants
showed high concordance [20].
Traditional chromosome analyses provided important
information on chromosomal aberrations in pancreatic
cancer and revealed a high degree of ploidy with many
chromosomal abnormalities [21]. Cytogenetic character-
ization of our new cell line performed by mFISH analysis
showed a hypertriploid complex karyotype with multiple
numerical and unbalanced structural aberrations.
According to previous studies, the recurrent chromo-
somal abnormalities seen in pancreatic cancer, such as
whole-chromosome losses of chromosomes 18, 21 and Y
as well as gains of chromosomes 11 and 20 were also
present in this cell line [22]. Furthermore, we observed
partial gains of chromosomes 8q and 12p, and partial
losses of 9p, 12q, and 17p, similar to previously reported
PDACs [23-25].
An increasing number of studies have demonstrated
that multiple genetic alteration steps are associated with
malignant progression in PDAC. Among these, the acti-
vation of the K-ras oncogene and inactivation of the p53
Table 2: Number of primary tumors/metastasis in mouse lung resulted from transplanted PaCa 5061 cells in vivo
Tumor Incidence Tumor weight (g) Median (range) Time of tumor growth (days) Median (range)
8/8 2.35 (1.38 - 4.4) 101 (99 - 163)
Metastasis Incidence Median (range)
6/8 724 (24 - 1948)
Figure 6 PaCa 5061 cell viability following Gemcitabine, 5-FU, Cetuximab, and Gefitinib treatment. Cell proliferation following drug treatment 
for 72 h was estimated by MTT test. 6A. Dose-dependent inhibition of cell proliferation in Gemcitabine and 5-FU treated cells as well as in Cetuximab 
and Gefitinib treated cells (6B). Quantitative values are means ± SEM from 3 independent experiments performed in quadruplicate.
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tumor suppressor gene have been proposed to play a piv-
otal role in PDAC progression [26,27]. Mutation of K-ras
gene was also detected in PaCa 5061 cells, in the xeno-
grafted tumors as well as in primary human tumor sam-
ples (activating mutation at codon 12). This finding is
consistent with previous studies which have reported that
the codon 12 mutation from GGT(Gly) to GAT(Asp) in
the K-ras gene is one of the most frequent mutations in
pancreatic cancer [28]. In contrast, neither inactivating
mutations of the p53 gene nor mutations that concerned
exons 18-21 of the EGFR gene were found.
A number of studies on pancreatic cancer have used
DNA microarrays in order to determine new molecular
markers and potential targets for treatment [29].
Microarray data of PaCa 5061 revealed recurrent regions
of amplification, including genes that are implicated in
cell proliferation (RAB18, ERBB3, MAP3K12, MIB1), sig-
nal transduction (STAT2, STAT6, IGFBP6), cell cycle or
cell migration (MMP19), all important genes for malig-
nant progression. In addition to these target genes we
identified an amplification of the chromosomal region
18q11.2 containing the gene for the transcription factor
GATA-6, whose gain and overexpression may play an
important and hitherto uninvestigated role in pancreatic
carcinogenesis [30]. For some other amplified genes,
MEMO1, IGFBP6, TBK1, MIB1 and RIOK3 we detected
an elevated RNA expression, suggesting an important
role in carcinogenesis of these cells. For some of these
genes putative roles in pancreatic adenocarcinoma pro-
gression have been identified, as RIOK3 [31] and
MEMO1 [32] or in tumor angiogenesis such as TBK1
[33]. Thus, the overexpression of the MEMO1 and the
TBK1 genes in PaCa 5061 cells could be associated with
the high tumorigenic and metastatic nature of these cells.
The elevation of gene expression promotes the optimal
proliferation and survival of cancer cells in their primary
environment by inhibition of apoptosis and enhancement
of the cell-division cycle, angiogenesis and invasion.
Among the genes specifically overexpressed in PaCa 5061
c e l l s  w e r e  n u m e r o u s  A K T -  a n d  M A P K -  k i n a s e s ,  a n d
some insulin growth factor binding proteins (IGFB-pro-
teins), molecules with pivotal roles in signal transduction.
AKT-kinases have been demonstrated to be major media-
tors of survival signals in a variety of cancer cells [34].
Furthermore, it was shown that AKT-kinases are capable
of suppression of apoptosis in a transcription-indepen-
dent manner through direct phosphorylation and inacti-
vation of the apoptotic machinery [35,36]. In fact, the
AKT gene is frequently amplified and the AKT protein is
constitutively active in more than 60% of pancreatic car-
cinomas [37,38]. The notion that the activation of signal
pathways associated with cell proliferation and resistance
to apoptosis may, at least partially, explain the aggressive-
ness of pancreatic cancer which is supported by our find-
ings that several mediators of such effects (amphiregulin,
heparin-binding EGF like growth factor, epiregulin and
vascular endothelial growth factor C) and their corre-
sponding receptors were upregulated.
Specific features of PDAC are tumor-growth into sur-
rounding vascular or visceral structures and an early
tumor spread to distant sites. These processes require
degradation of the surrounding extracellular matrix by
matrix metalloproteinases (MMPs) [39,40]. Indeed, we
found several MMPs (MMP-10, MMP-28) to be upregu-
lated in PaCa 5061. Recently, MMP-10 was shown to be
specifically upregulated and involved in metastatic
spread to the liver in xenografts of pancreatic cancer [41].
Hence, MMPs become more and more attractive as tar-
gets for anti-cancer drugs.
The top hits of overexpressed genes (fold change > 10)
were Mucin 4 (MUC4) and some family members of the
carcinoembryonic antigen-related adhesion molecules
(CEACAM 1, CEACAM 5 and CEACAM 6). MUC4, a
high-molecular weight glycoprotein with a multidomain
organization, plays multifunctional role in cell physiology
[42,43]. MUC4 has already been linked to PDAC as an
aberrantly expressed gene with no detectable expression
in normal pancreas or chronic pancreatitis [44,45].
Recent studies have shown that MUC4 is implicated in
modulation of ErbB2 signalling, in repression of apopto-
sis, in regulation of cell adhesion, in promoting tumor
progression and metastasis, and in multidrug resistance
processes [46]. The fact that elevated MUC4 expression
occurs in the majority (70-80%) of pancreatic carcinomas,
most notably at early onset of disease progression, leads
to the discussion of MUC4 as a new tumor marker for
this deadly disease [47]. Our results would corroborate
this hypothesis.
To our knowledge, the simultaneous overexpression of
CEACAM-1, -5 and -6 proteins in pancreatic cancer cells
has not been reported before. CEACAMs belong to the
family of mammalian immunoglobulin-related glycopro-
teins, which are involved in cell-cell recognition and
modulate cellular processes that range from the shaping
of tissue architecture to (tumor) neovascularization. It
was shown that CEACAM expression is elevated in many
solid tumors [48,49]. Functionally, CEACAMs have been
implicated in cell adhesion, cellular invasiveness, resis-
tance to anoikis and drug treatment, and to metastatic
behaviour of tumor cells [50-53]. Therefore, the elevated
CEACAM 1, -5 and -6 and MUC4 levels in PaCa 5061
cells may well contribute to the high metastatic potential
of these cells as well.
In comparison with other gastrointestinal malignan-
cies, pancreatic cancer seems to be one of the most resis-
tant cancers to chemotherapy [54]. Therefore, we
evaluated the cytotoxic effects of two standard chemo-
therapeutic drugs, Gemcitabine and 5-FU, and two tar-Kalinina et al. BMC Cancer 2010, 10:295
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geted therapeutics, Gefinitib and Cetuximab, on PaCa
5061 cells. These drugs show a limited efficacy with
regard to tumor response and prolongation of patient
survival [55]. Consistently, PaCa 5061 cells were highly
resistant to both, Gemcitabine and 5-FU. The molecular
and biological mechanisms why most pancreatic cancer
cells are insensitive to chemotherapy and escape the cyto-
toxic effects are largely unknown.
Conclusion
Our newly established pancreatic cancer cell line, PaCa
5061, highly resembles the in vivo tumor biology of
PDAC. Because of its similarity to the original human
tumor, it offers an ideal in vivo model for the evaluation
of drug-resistance and novel therapeutic approaches, in
particular those which target cancer cell dissemination or
metastatic spread of this deadly neoplasia.
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